Brought to you by 
Santen Pharmaceutical acquires 50.55% of Novagali Pharma
13 Oct 2011
Executive Summary
Japanese pharmaco Santen Pharmaceutical Co. Ltd. has agreed to buy 50.55% of French ophthalmic therapeutics developer Novagali Pharma SA for €50.7mm ($69.5mm) in cash, or about €6.15 per share (a 77% premium). After the initial transaction, Santen will purchase the remaining shares for the same price; if it acquires at least 95% of Novagali, the price will be increased to €6.25.
Deal Industry
- Biotechnology
- Medical Devices
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Site Specific
- Topical Delivery
-
Drug Delivery
Deal Status
- Final
Deal Type
-
Acquisition
- Partial Acquisition
- Payment Includes Cash
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Santen Pharmaceutical acquires 50.55% of Novagali Pharma
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice